Researcher Blocks Protein that Defeats Powerful Tumor Suppressor in Breast Cancer
Sanjay Awasthi, M.D., targets breast cancer prevention with new insights to the p53 gene.
Over half of all breast cancers carry genetic defects in the p53 gene, a powerful
tumor suppressor. Loss of this gene increases the risk of getting breast cancer and
the resultant cancers become highly resistant to treatment.
Researchers at the Texas Tech University Health Sciences Center (TTUHSC) School of
Medicine have blocked the protein to defeat the effects of p53 loss more effectively
than any existing cancer medicine.
Sanjay Awasthi, M.D., a professor in the TTUHSC Department of Internal Medicine and
an oncologist, received a Department of Defense $1,147,500 grant for his research,
“Prevention of Breast Cancer by Haploinsufficiency of RALBP1.”
“Despite decades of research, there had been no satisfactory way to overcome the deleterious
effects of p53 loss – until now,” Awasthi said. “We showed for the first time that
blocking the stress-responsive protein called Rlip (Rlip76 or RALBP1) defeats the
deleterious effects of p53 loss more effectively. This discovery is a game changer
in cancer treatment because more than half of all types of cancers lack normal p53.”
Li-Fraumeni Syndrome (LFS) is a hereditary cancer predisposition syndrome reported
in 1969 by Drs. Frederick Li and Joseph Fraumeni. Approximately 1 out of every 10,000
people have the syndrome and can be afflicted with cancers that are difficult to treat
and often reoccurring. Awasthi said there has been no way of stopping cancer because
those who have the syndrome are missing a gene.
Awasthi will test a chemical derived from oranges, a phosphorothioate antisense directed towards Rlip.
“P53 is called the guardian of the genome because it is essential for regulating cell
division and preventing tumor formation,” Awasthi said “If it is missing the genes
that cause cancer, then they become abnormal and essentially cause cancer in a large
number of people. About 68 percent of all cancers have an abnormality of this gene
and some of those have a complete loss of the gene.”
In order to study this disease, a mouse was created almost 3 decades ago that always
gets cancer and dies at 6 months. Now with this current research, there is a 100 percent
suppression of the cancer.
“I had the opportunity to meet Dr. Fraumini and say, ‘look, I can cure your mice,’”
Awasthi said.
This research began more than 40 years ago with Awasthi’s father, Yogesh C Awasthi,
who worked on an enzyme that defends the body from toxins. Sanjay Awasthi solved the
last step with research experiments in 1982 and a protein cloned in 2003. In 2009,
he had the first successful company called Terapio, which develops therapeutics based
on the Rlip76 protein
Now, this DOD grant will allow TTUHSC researchers to target how to prevent breast
cancer. Awasthi will test a chemical that is derived from oranges, which is where
he found the chemical, a phosphorothioate antisense directed towards Rlip, that activates
this medicine as well as addressing other health issues.
“By giving this protein, I also can help someone with radiation poisoning,” Awasthi
said. The DOD helped us make the medicine. The other significant benefit is that this
medication reverses drug resistance to chemotherapy and other drug resistances.”
Remarkably, drugs that block Rlip also reduce blood sugar, cholesterol and triglycerides. Awasthi’s
findings will lead to highly effective new medications for cancer, diabetes, obesity
and hyperlipidemia.
Related Stories
Noise-Induced Hearing Loss in Rural Adolescents
Leigh Ann Reel, Au.D., Ph.D., CCC-A, discussed the causes and prevention strategies for noise-induced hearing loss, particularly for adolescents in rural areas.
Willed Body Memorial Service Honors Those Who Donated
On Memorial Day each May, a service is conducted at the Texas Tech University Health Sciences Center Institute of Anatomical Sciences to pay respect to the Willed Body Program donors and their families.
Molecular Pathology Preceptorship: Unmatched Value and Experience
Ericka Hendrix, PhD, MB(ASCP)CM, Program Director and Associate Professor in the Master of Science in Molecular Pathology program in the School of Health Professions spoke about the program’s preceptorship.
Recent Stories
Logsdon Receives Grant to Study Vascular Side of Traumatic Brain Injuries
Supported by a three-year, $578,211 grant from the National Institutes of Health-National Institute on Aging, Aric F. Logsdon, Ph.D., will study how brain endothelial cells, or blood vessels within the brain, handle the stressors of neuroinflammation.
Historic collaboration brings shipping container-based health care clinic to Jeff Davis County
Texas A&M Health and TTUHSC joined with the student-led organization, Texas A&M BUILD—along with local leadership and other collaborators—to unveil a new, innovative medical care facility for a Trans-Pecos region rural community: a 40-foot, retro-fitted shipping container.
Improving Health Care Access, Education Through Research
The service area for TTUHSC, a recognized leader in academic health and biomedical research training, encompasses 121 Texas counties.